COMPASS Pathways Plc - Form 8-K Summary
Business Context and Reporting Period
Company: COMPASS Pathways Plc (CMPS)
Filing Date: January 5, 2026
Reporting Period: Current Report (Event Date: January 5, 2026)
Event: Entry into a Material Definitive Agreement (Third Amendment to Loan and Security Agreement with Hercules Capital, Inc.).
Key Financial Metrics and Debt Structure
This filing details a new debt facility rather than operational financial results (revenue, profit, or cash flow are not reported in this document).
- Total Facility Size: Up to $150.0 million in term loans across five tranches.
- Immediate Funding (Tranche 1): $50.0 million fully funded on the Closing Date.
- Use of Proceeds: Approximately $31.1 million used to repay outstanding principal and PIK interest under the existing loan agreement.
- Interest Rate: The greater of 9.75% or 2.75% plus the Wall Street Journal prime rate.
- Repayment Terms: Interest-only payments until the first principal payment is due in Q1 2029 (subject to deferral based on milestones). Maturity date is January 5, 2031.
- Upfront Fees: $250,000 facility charge paid on the Closing Date.
- End of Term Charge: 7.75% of the principal amount prepaid or repaid.
- Existing Obligation: A remaining unpaid end-of-term charge of $1.425 million from the prior agreement is payable by July 1, 2027, or upon full prepayment of Tranche 1.
Material Changes and Milestone Conditions
The Third Amendment restructures the company's debt obligations with Hercules Capital, Inc., replacing the existing loan agreement. Future funding is contingent on specific milestones:
- Tranche 2 (Up to $30.0 million): Subject to achieving a clinical milestone.
- Tranche 3 (Up to $30.0 million): Subject to achieving FDA approval milestones.
- Tranche 4 (Up to $20.0 million): Subject to achieving a commercial milestone.
- Tranche 5 (Up to $20.0 million): Subject to Hercules' investment committee approval and availability of unborrowed amounts from Tranches 2-4.
Guidance, Risks, and Covenants
Covenants:
- Financial Covenant: Requires maintaining specific cash levels in accounts (subject to change based on milestones) under a control agreement commencing July 1, 2026.
- Performance Covenant: Applies if $75.0 million or more is drawn; requires maintaining certain net product revenue levels starting nine months after FDA approval of the lead product candidate.
Risks and Contingencies:
- Collateral: Borrowings are secured by all personal property and assets, excluding certain intellectual property rights and deposit accounts.
- Prepayment Penalties: Prepayment premiums range from 2.0% (Year 1) to 0.5% (Year 3+).
- Default Consequences: Events of default include payment defaults, covenant breaches, and material adverse effects. Default triggers an additional 4.0% interest rate and immediate acceleration of all obligations.
- Lender Rights: Hercules retains a right to invest up to $5.0 million in future financings.
Investor Verification Checklist
- Verify the exact cash balance remaining after the $31.1 million repayment and $250,000 fee payment from the $50.0 million Tranche 1 advance.
- Confirm the specific clinical and commercial milestones required to unlock the remaining $100.0 million in potential funding.
- Review the "control agreement" terms regarding cash maintenance starting July 1, 2026, to understand liquidity restrictions.
- Assess the impact of the 7.75% end-of-term charge on future refinancing or prepayment strategies.
- Monitor the timeline for FDA approval of the lead product candidate, as this triggers the performance covenant and potential deferral of principal payments.